Lori Burnside Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 205 W College Ave, Devine, TX 78016 Phone: 830-851-0732 |
News Archive
NicOx S.A. has announced the results of a dose-ranging phase 2 study conducted with PF‑03187207 in Japanese patients with glaucoma by its partner Pfizer Inc. PF-03187207 is a nitric oxide-donating prostaglandin analog. The study was designed to compare the safety and efficacy of several doses of PF-03187207 to Xalatan (latanoprost) and enrolled 112 Japanese patients with primary open-angle glaucoma or ocular hypertension.
As many as 35 percent of Mexican young adults may have a genetic predisposition for obesity, said a University of Illinois scientist who conducted a study at the Universidad Aut-noma de San Luis Potosί.
Buffers that guard against damage to the ends of chromosomes could hold the key to a better understanding of malignant melanoma - the deadliest form of skin cancer - according to new research from the University of Leeds.
Bayer HealthCare announced today that data on its investigational pulmonary hypertension compound riociguat (BAY 63-2521) will be presented in a scientific forum at the American College of Chest Physicians (ACCP) annual meeting October 20 – 25, in Atlanta, GA.
Tuberculosis remains a rare disease in the United States, but when it does occur, delays in diagnosing it often exceed recommendations by the World Health Organization, according to a new report by Harvard Medical School researchers published March 22 in The Lancet Infectious Diseases.
› Verified 2 days ago